A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy

Clinical Oncology

Volumn 17, Issue 6, 2005, Pages 418-424

  León, Xavier ^a   Constenla, M ^b   Rocca, A ^c   Stupp, R ^d   Kovacs A F ^e   Amellal, N ^f   Bessa, E H ^g   Bourhis, J ^h  

^a Hospital Sant Pau   (Spain)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c HOSPITAL MONTECELO   (Spain)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^g MERCK KGAA   (Germany)

^h INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Patient outcome; SCCHN; Second line therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; METHOTREXATE; NAVELBINE; NOLATREXED; PLATINUM DERIVATIVE; UFT;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; EUROPE; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23744495620     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2005.02.014     Document Type: Article

References (42)

1. R.J. Black F. Bray J. Ferlay D.M. Parkin Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990 Eur J Cancer 33 1997 1075-1107
2. E.E. Vokes R.R. Weichselbaum S.M. Lippman W.K. Hong Head and neck cancer N Engl J Med 328 1993 184-194
3. E.S. Kim B.S. Glisson Treatment of metastatic head and neck cancer: chemotherapy and novel agents Cancer Treat Res 114 2003 295-314
4. J. Kao M.C. Garofalo M.T. Milano S.J. Chmura J.R. Citron D.J. Haraf Reirradiation of recurrent and second primary head and neck malignancies: A comprehensive review Cancer Treat Rev 29 2003 21-30
5. R. De Crevoisier J. Bourhis C. Domenge et al. Full-dose reirradiation for unresectable head and neck carcinoma: Experience at the Gustave-Roussy Institute in a series of 169 patients J Clin Oncol 16 1998 3556-3562
6. A. Puthawala A.M. Nisar Syed S. Gamie Y.J. Chen A. Londrc V. Nixon Interstitial low-dose-rate brachytherapy as a salvage treatment for recurrent head-and-neck cancers: Long-term results Int J Radiat Oncol Biol Phys 51 2001 354-362
7. U. Schaefer O. Micke P. Schueller N. Willich Recurrent head and neck cancer: Retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study Radiology 216 2000 371-376
8. J.A. Ridge Squamous cancer of the head and neck: Surgical treatment of local and regional recurrence Semin Oncol 20 1993 419-429
9. P.M. Stell R.P. Morton I.T. Campbell J.A. Wilson Survival after "palliative" cytotoxic chemotherapy for head-and-neck cancer Lancet 2 1983 1205
10. D.O. Constenla M.E. Hill R.P. A'Hern et al. Chemotherapy for symptom control in recurrent squamous cell carcinoma of the head and neck Ann Oncol 8 1997 445-449
11. C. Jacobs G. Lyman E. Velez-Garcia et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck J Clin Oncol 10 1992 257-263
12. M. Clavel J.B. Vermorken F. Cognetti et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group Ann Oncol 5 1994 521-526
13. A.A. Forastiere B. Metch D.E. Schuller et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study J Clin Oncol 10 1992 1245-1251
14. A.A. Forastiere T. Leong E. Rowinsky et al. Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393 J Clin Oncol 19 2001 1088-1095
15. B. Murphy Y. Li D. Cella A. Karnad M. Hussain A. Forastiere Phase III study comparing cisplatin (C) & 5-flurouracil (F) versus cisplatin & paclitaxel (T) in metastatic/recurrent head & neck Cancer (MHNC) [abstract 894] Proc Am Soc Clin Oncol 2001
16. C. Hopper C. Niziol M. Sidhu The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK Oral Oncol 40 2004 372-382
17. A.B. Miller B. Hoogstraten M. Staquet A. Winkler Reporting results of cancer treatment Cancer 47 1981 207-214
18. X. Pivot S. Wadler C. Kelly et al. Result of two randomized trials comparing nolatrexed (Thymitaq) versus methotrexate in patients with recurrent head and neck cancer Ann Oncol 12 2001 1595-1599
19. A. Testolin G. Recher V. Cristoferi G. Gasparini Vinorelbine in pre-treated advanced head & neck squamous cell carcinoma. A phase II study Invest New Drugs 12 1994 231-234
20. C. Porta S. Brugnatelli E. Patruno et al. Single-agent vinorelbine (VRB) as second-line treatment for advanced or recurrent squamous-cell carcinoma of the head and neck (SCCHN) [abstract 2537] Proc Am Soc Clin Oncol 2001
21. G. Numico M. Merlano Second-line treatment with docetaxel after failure of a platinum-based chemotherapy in squamous-cell head and neck cancer Ann Oncol 13 2002 331-333
22. T.W. Brotherton P. Ritch T. Ervin D. Hanson J. Wade A. Forastiere Phase II multicenter trial of PACLITAXEL (Taxol) (T) weekly one hour infusion in previously treated advanced head/neck cancer (AHNC) [abstract 921] Proc Am Soc Clin Oncol 2001
23. M. Merlano A. Bacigalupo M. Benasso et al. 5-Fluorouracil and high-dose folinic acid as second-line chemotherapy in head and neck cancer Am J Clin Oncol 13 1990 1-3
24. V. Gebbia R. Valenza A. Testa et al. Methotrexate, vinblastine, epidoxorubicin, and bleomycin as second-line chemotherapy for recurrent and/or metastatic squamous cell carcinoma of the head and neck ORL J Otorhinolaryngol Relat Spec 56 1994 279-282
25. A. Iop G. Cartei A. Isaia Vinorelbine, bleomycin and methotrexate as a salvage therapy for patients with head and neck squamous carcinoma in relapse after cisplatin/fluorouracil Ann Oncol 9 1998 225-227
26. P. Dodion F. Cognetti M. van Rymenant O. Dalesio A. Kirkpatrick M. Rozencweig Phase II study of a combination of hydroxyurea, fluorouracil and mitomycin in previously treated squamous cell carcinoma of the head and neck Eur J Cancer Clin Oncol 22 1986 241-243
27. M. Benasso G. Numico M. Merlano Carboplatin and 5-fluorouracil in squamous cell carcinoma of the head and neck previously responding to cisplatin and 5-fluorouracil Eur J Cancer 33 1997 318-319
28. G.P. Stathopoulos S. Rigatos P. Papakostas G. Fountzilas Effectiveness of paclitaxel and carboplatin combination in heavily pretreated patients with head and neck cancers Eur J Cancer 33 1997 1780-1783
29. J.B. Vermorken G. Catimel P.D. Mulder et al. Randomized phase II trial of weekly methotrexate (MTX) versus two schedules of triweekly paclitaxel (Taxol[trade]) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN) [abstract 1527] Proc Am Soc Clin Oncol 1999
30. D.S. Salomon R. Brandt F. Ciardiello N. Normanno Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183-232
31. O. Dassonville J.L. Formento M. et al. Francoual Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer J Clin Oncol 11 1993 1873-1878
32. G.J. Rubin M.F. Melhem W.E. Gooding et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival J Natl Cancer Inst 90 1998 824-832
33. R.I. Nicholson J.M. Gee M.E. Harper EGFR and cancer prognosis Eur J Cancer 37 Suppl 4 2001 S9-S15
34. C. Kari T.O. Chan D.Q. Rocha U. Rodeck Targeting the epidermal growth factor receptor in cancer: Apoptosis takes center stage Cancer Res 63 2003 1-5
35. A. Wells Tumor invasion: Role of growth factor-induced cell motility Adv Cancer Res 78 2000 31-101
36. J. Baselga The EGFR as a target for anticancer therapy: Focus on cetuximab Eur J Cancer 37 Suppl 4 2001 S16-S22
37. E.E. Cohen F. Rosen W.M. Stadler et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck J Clin Oncol 21 2003 1980-1987
38. D. Soulieres N.N. Senzer E.E. Vokes M. Hidalgo S.S. Agarwala L.L. Siu Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck J Clin Oncol 22 2004 77-85
39. N.I. Goldstein M. Prewett K. Zuklys P. Rockwell J. Mendelsohn Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model Clin Cancer Res 1 1995 1311-1318
40. J. Baselga J.M. Trigo J. Bourhis J. Tortochaux H. Cortes-Funes R. Hitt et al. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen [abstract 900] Proc Am Soc Clin Oncol 2002
41. M.S. Kies M.A. Arquette L. Nabell et al. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing chemotherapy [abstract 925] Proc Am Soc Clin Oncol 2002
42. J. Trigo R. Hitt P. Koralewski et al. Cetuximab (Erbitux™) monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): Results of a phase II study [abstract 1947] Proc Am Soc Clin Oncol 2004